Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Discovery of first-in-class precision antibody drug conjugates with a potent SMARCA2/4 dual degrader payload

Friday, November 22, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery of a novel class of precision antibody drug conjugates featuring a powerful SMARCA2/4 dual degrader payload. This advancement is expected to enhance the effectiveness of targeted cancer treatments. The research highlights the innovative approach taken by the team to develop these conjugates.
Price reaction · baseline $0.9672 (2024-11-21 close) · hit pre-market · 2 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of first-in-class precision antibody drug conjugates.
  • Development of a potent SMARCA2/4 dual degrader payload.
  • Potential to advance targeted cancer therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Carter J, Agarwal A, Sivakumar M, Reichelderfer A, Park J, Osinubi O, Holmes R, Fultang N, Schwab A, Rager J, Stahl N, Cote J, Crossan A, Chen C, Pawley S, Wang M, Geeganage S, Lee S, Combs A, Scherle P, Buesking A and Ito K

Frequently Asked Questions

What are precision antibody drug conjugates?

Precision antibody drug conjugates are targeted therapies designed to deliver cytotoxic agents directly to cancer cells.

What is the significance of the SMARCA2/4 dual degrader payload?

The SMARCA2/4 dual degrader payload enhances the efficacy of the drug conjugates by targeting specific cancer pathways.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare SMARCA2 SMARCA4 cancer therapies drug conjugates
Last updated: Nov 22, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →